CSPC Innovation Pharmaceutical (300765.SZ) subsidiary SYS6002 presents research findings at the 2026 International Gynecologic Cancer Society Global Annual Meeting

CSPC Innovation Pharmaceutical (300765.SZ) announced that its controlling subsidiary, CSPC PHARMA Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as "Jushi Biopharmaceutical"), presented Phase I clinical study data for SYS6002 monotherapy in the treatment of advanced cervical cancer in a rapid oral presentation at the 2026 International Gynecologic Cancer Society Global Annual Meeting (IGCS Annual Global Meeting), held from October 1 to October 3 in Montreal, Canada. SYS6002 is a next-generation antibody-drug conjugate (ADC) targeting Nectin-4. The drug employs enzyme-catalyzed site-specific antibody conjugation technology to deliver the potent mitotic inhibitor MMAE specifically to Nectin-4-expressing cancer cells. Its stable linker design not only facilitates the delivery of high concentrations of MMAE to tumors but also reduces toxicity by lowering systemic exposure to the toxin. The relevant safety and efficacy data are as follows: In terms of safety, the safety profiles of the two dose groups were generally manageable, with treatment-related adverse events mostly Grade 1-2. Among these, ocular-related adverse events were the most common, but no Grade 3 or above events were observed, and no patient discontinued treatment due to these events. The incidence of interstitial lung disease and non-infectious pneumonia was low (2.4%). The incidence and severity of treatment-related rash were both low (any grade: 20.7%; Grade 3: 1.2%), with no cases of Stevens-Johnson syndrome or toxic epidermal necrolysis. The incidence and severity of peripheral neuropathy were also low (12.2%; all Grade 1-2). No treatment-related adverse events leading to death occurred. In terms of efficacy, both dosing regimens demonstrated preliminary efficacy in the study population. The confirmed objective response rate was 35.9% for the 2.4 mg/kg once every 2 weeks dose group and 28.6% for the 3.6 mg/kg once every 3 weeks dose group. The median duration of response for patients achieving confirmed response in the two groups was 8.2 months and 10.3 months, respectively; the median progression-free survival was 4.1 months and 4.3 months, respectively; and the median overall survival was 15.1 months and 11.5 months, respectively.